Protocol Ledger

NCT04895241 · Phase III · ACTIVE NOT RECRUITING

A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

Interventional Phase III clinical trial protocol NCT04895241 sponsored by Biogen in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-05-25 Enrollment: 548 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04895241
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)548 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04895241
Protocol FieldVerified Registry Value
NCT IdentifierNCT04895241
Consolidated Lead SponsorBiogen
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment548 participants (ACTUAL)
Registered Start Date2021-05-25
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Biogen across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI